الفهرس | Only 14 pages are availabe for public view |
Abstract FGF23 is a new emerging factor in medical field it is thought to be responsible for phosphate metabolism by increasing its excretion in renal impairment patients and decrease vitamin D level in them. It is thought that its expression increases in multiple myeloma patients increasing heparenase. Heparenase is an osteolytic factor which increases morbidity in multiple myeloma patients. So studies were done on FGF23 with a hope that we can use it to predict stages of renal impairment, control vitamin D decline in renal impairment or stop FGF23 axis in multiple myeloma as this axis thought to increase morbidity in multiple myeloma patient. In our study we measured IFGF23 level in multiple myeloma patients with and without renal impairment and compared results with renal impairment patients without multiple myeloma and healthy individuals. Serum iFGF23 was higher in patients with multiple myeloma than the control subjects (P < 0.01). Serum iFGF23 level higher in multiple myeloma patients with renal impairment than those without renal imparment (p<0.05) Serum iFGF23 level higher in renal impairment patients than in healthy individuals (p<0.01). There is significant direct correlation between iFGF23 and creatinine (p<0.01), (r=0.689). (111 ) Summary Serum iFGF23 is significantly inversely proportional to eGFR (p<0.01), (r=0.678). We found that FGF23 is not correlated to Hb, Na, k, LDH, ca, B2 micro, BM plasma cells, D bilirubin, ALT, AST. Moreover it was found in our study that FGF23 has a cut off point greater than or equal to 135pg/ml to predict multiple myeloma patients with renal impairment from multiple myeloma without renal impairment with sensitivity 70% and specificity 75%. However we discovered that FGF23 has a cut off point greater than or equal to 62.5pg/ml to predict multiple myeloma patients from healthy individuals with sensitivity 80%. |